Ravi Doddapaneni

1.3k total citations
33 papers, 1.1k citations indexed

About

Ravi Doddapaneni is a scholar working on Molecular Biology, Oncology and Biomaterials. According to data from OpenAlex, Ravi Doddapaneni has authored 33 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 10 papers in Oncology and 8 papers in Biomaterials. Recurrent topics in Ravi Doddapaneni's work include Nanoparticle-Based Drug Delivery (8 papers), Nanoplatforms for cancer theranostics (6 papers) and RNA Interference and Gene Delivery (5 papers). Ravi Doddapaneni is often cited by papers focused on Nanoparticle-Based Drug Delivery (8 papers), Nanoplatforms for cancer theranostics (6 papers) and RNA Interference and Gene Delivery (5 papers). Ravi Doddapaneni collaborates with scholars based in United States, India and South Korea. Ravi Doddapaneni's co-authors include Mandip Singh, Chandraiah Godugu, Ketan Patel, Apurva R. Patel, Nusrat Chowdhury, Stephen Safe, Cedar H. A. Boakye, Srujan Marepally, Erik Hedrick and Syng‐Ook Lee and has published in prestigious journals such as PLoS ONE, Molecular and Cellular Biology and Cancer Research.

In The Last Decade

Ravi Doddapaneni

33 papers receiving 1.1k citations

Peers

Countries citing papers authored by Ravi Doddapaneni

Since Specialization

Citations

This map shows the geographic impact of Ravi Doddapaneni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ravi Doddapaneni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ravi Doddapaneni more than expected).

Fields of papers citing papers by Ravi Doddapaneni

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ravi Doddapaneni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ravi Doddapaneni. The network helps show where Ravi Doddapaneni may publish in the future.

Co-authorship network of co-authors of Ravi Doddapaneni

This figure shows the co-authorship network connecting the top 25 collaborators of Ravi Doddapaneni. A scholar is included among the top collaborators of Ravi Doddapaneni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ravi Doddapaneni. Ravi Doddapaneni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Synergistic Effect of Ribitol and Shikonin Promotes Apoptosis in Breast Cancer Cells 2025 ·International Journal of Molecular Sciences ·Ravi Doddapaneni, (unknown), Pei Lu, Qi Long Lu	2
2	Metabolic Reprogramming by Ribitol Expands the Therapeutic Window of BETi JQ1 against Breast Cancer 2023 ·Cancers ·Ravi Doddapaneni, (unknown), Pei Lu, Qi Long Lu	2
3	Ribitol alters multiple metabolic pathways of central carbon metabolism with enhanced glycolysis: A metabolomics and transcriptomics profiling of breast cancer 2022 ·PLoS ONE ·(unknown), Ravi Doddapaneni, Pei Lu, Qi Long Lu	12
4	Erlotinib-Valproic Acid Liquisolid Formulation: Evaluating Oral Bioavailability and Cytotoxicity in Erlotinib-Resistant Non-small Cell Lung Cancer Cells 2019 ·AAPS PharmSciTech ·Ketan Patel, Ravi Doddapaneni, Manali Patki, (unknown), Arvind Bagde, Mandip Singh	21
5	Honokiol nanomicellar formulation produced increased oral bioavailability and anticancer effects in triple negative breast cancer (TNBC) 2017 ·Colloids and Surfaces B Biointerfaces ·Chandraiah Godugu, Ravi Doddapaneni, Mandip Singh	56
6	Liposomes co-Loaded with 6-Phosphofructo-2-Kinase/Fructose-2, 6-Biphosphatase 3 (PFKFB3) shRNA Plasmid and Docetaxel for the Treatment of non-small Cell Lung Cancer 2017 ·Pharmaceutical Research ·Nusrat Chowdhury, Imran Vhora, Ketan Patel, Ravi Doddapaneni, Arindam Mondal, Mandip Singh	28
7	Cholecalciferol-PEG Conjugate Based Nanomicelles of Doxorubicin for Treatment of Triple-Negative Breast Cancer 2017 ·AAPS PharmSciTech ·Shallu Kutlehria, Gautam Behl, Ketan Patel, Ravi Doddapaneni, Imran Vhora, Nusrat Chowdhury, Arvind Bagde, Mandip Singh	31
8	Therapeutic targeting of oncogenic transcription factors by natural products in eye cancer 2017 ·Pharmacological Research ·(unknown), John Y. Lee, Ryan A. Gallo, Wensi Tao, David Tse, Ravi Doddapaneni, Daniel Pelaez	12
9	Reversal of drug-resistance by noscapine chemo-sensitization in docetaxel resistant triple negative breast cancer 2017 ·Scientific Reports ·Ravi Doddapaneni, Ketan Patel, Nusrat Chowdhury, Mandip Singh	35
10	Novel amphiphilic lipid augments the co-delivery of erlotinib and IL36 siRNA into the skin for psoriasis treatment 2016 ·Journal of Controlled Release ·Cedar H. A. Boakye, Ketan Patel, Ravi Doddapaneni, Arvind Bagde, Srujan Marepally, Mandip Singh	62
11	Novel diindolylmethane derivatives based NLC formulations to improve the oral bioavailability and anticancer effects in triple negative breast cancer 2016 ·European Journal of Pharmaceutics and Biopharmaceutics ·Chandraiah Godugu, Ravi Doddapaneni, Stephen Safe, Mandip Singh	39
12	Nuclear receptor 4A1 (NR4A1) as a drug target for treating rhabdomyosarcoma (RMS) 2016 ·Oncotarget ·(unknown), Erik Hedrick, Xi Li, Ketan Patel, Ravi Doddapaneni, Mandip Singh, Stephen Safe	25
13	Ultra-flexible nanocarriers for enhanced topical delivery of a highly lipophilic antioxidative molecule for skin cancer chemoprevention 2016 ·Colloids and Surfaces B Biointerfaces ·Cedar H. A. Boakye, Ketan Patel, Ravi Doddapaneni, Arvind Bagde, Gautam Behl, Nusrat Chowdhury, Stephen Safe, Mandip Singh	30
14	Novel Gefitinib Formulation with Improved Oral Bioavailability in Treatment of A431 Skin Carcinoma 2015 ·Pharmaceutical Research ·Chandraiah Godugu, Ravi Doddapaneni, Apurva R. Patel, Rakesh K. Singh, Roger S. Mercer, Mandip Singh	39
15	Nuclear receptor 4A1 as a drug target for breast cancer chemotherapy 2015 ·Endocrine Related Cancer ·Erik Hedrick, Syng‐Ook Lee, Ravi Doddapaneni, Mandip Singh, Stephen Safe	49
16	Piperlongumine for Enhancing Oral Bioavailability and Cytotoxicity of Docetaxel in Triple-Negative Breast Cancer 2015 ·Journal of Pharmaceutical Sciences ·Ketan Patel, Nusrat Chowdhury, Ravi Doddapaneni, Cedar H. A. Boakye, Chandraiah Godugu, Mandip Singh	55
17	Evaluation of self-emulsified DIM-14 in dogs for oral bioavailability and in Nu/nu mice bearing stem cell lung tumor models for anticancer activity 2015 ·Journal of Controlled Release ·Apurva R. Patel, Ravi Doddapaneni, Terrick Andey, Heather Wilson‐Robles, Stephen Safe, Mandip Singh	12
18	Approaches to Improve the Oral Bioavailability and Effects of Novel Anticancer Drugs Berberine and Betulinic Acid 2014 ·PLoS ONE ·Chandraiah Godugu, Apurva R. Patel, Ravi Doddapaneni, (unknown), Mandip Singh	125
19	Overexpression of microRNA‐122 enhances in vitro hepatic differentiation of fetal liver‐derived stem/progenitor cells 2013 ·Journal of Cellular Biochemistry ·Ravi Doddapaneni, Yogesh Chawla, Ashim Das, Jasvinder Kalra, Sujata Ghosh, Anuradha Chakraborti	39
20	Inhalation delivery of Telmisartan enhances intratumoral distribution of nanoparticles in lung cancer models 2013 ·Journal of Controlled Release ·Chandraiah Godugu, Apurva R. Patel, Ravi Doddapaneni, Srujan Marepally, Tanise Jackson, Mandip Singh	68

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact